Professor EMAD RAKHA's Outputs (199)

Co-Expression Effect of SLC7A5/SLC3A2 to Predict Response to Endocrine Therapy in Oestrogen-Receptor-Positive Breast Cancer (2020)
Journal Article
Alfarsi, L. H., El-Ansari, R., Craze, M. L., Masisi, B. K., Mohammed, O. J., Rakha, E. A., Ellis, I. O., & Green, A. R. (2020). Co-Expression Effect of SLC7A5/SLC3A2 to Predict Response to Endocrine Therapy in Oestrogen-Receptor-Positive Breast Cancer. International Journal of Molecular Sciences, 21(4), Article 1407. https://doi.org/10.3390/ijms21041407

The majority of breast cancers are oestrogen receptor positive (ER+) and are subject to endocrine therapy however, an unpredictable subgroup of patients will develop resistance to endocrine therapy. SLC7A5/SLC3A2 complex is a major route for the tran... Read More about Co-Expression Effect of SLC7A5/SLC3A2 to Predict Response to Endocrine Therapy in Oestrogen-Receptor-Positive Breast Cancer.

XRCC1 deficient triple negative breast cancers are sensitive to ATR, ATM and Wee1 inhibitor either alone or in combination with olaparib (2020)
Journal Article
Ali, R., Alblihy, A., Toss, M. S., Algethami, M., Al Sunni, R., Green, A. R., Rakha, E. A., & Madhusudan, S. (2020). XRCC1 deficient triple negative breast cancers are sensitive to ATR, ATM and Wee1 inhibitor either alone or in combination with olaparib. Therapeutic Advances in Medical Oncology, 12, 175883592097420. https://doi.org/10.1177/1758835920974201

Background: PARP inhibitor (PARPi) monotherapy is a new strategy in BRCA germ-line deficient triple negative breast cancer (TNBC). However, not all patients respond, and the development of resistance limits the use of PARPi monotherapy. Therefore, th... Read More about XRCC1 deficient triple negative breast cancers are sensitive to ATR, ATM and Wee1 inhibitor either alone or in combination with olaparib.

A quantitative centrosomal amplification score predicts local recurrence in ductal carcinoma in situ (2020)
Journal Article
Mittal, K., Toss, M. S., Wei, G., Choi, D. H., Melton, B. D., Osan, R. M., Milligy, I. M., Green, A. R., Janssen, E. A., Søiland, H., Gogineni, K., Manne, U., Rida, P., Rakha, E. A., & Aneja, R. (2020). A quantitative centrosomal amplification score predicts local recurrence in ductal carcinoma in situ. Clinical Cancer Research, 26(12), 2898-2907. https://doi.org/10.1158/1078-0432.ccr-19-1272

The prognostic value of the tumor–stroma ratio is most discriminative in patients with grade III or triple‐negative breast cancer (2020)
Journal Article
Vangangelt, K. M., Green, A. R., Heemskerk, I. (. F., Cohen, D., Van Pelt, G. W., Sobral-Leite, M., Schmidt, M. K., Putter, H., Rakha, E. A., Tollenaar, R. A., & Mesker, W. E. (2020). The prognostic value of the tumor–stroma ratio is most discriminative in patients with grade III or triple‐negative breast cancer. International Journal of Cancer, 146(8), 2296-2304. https://doi.org/10.1002/ijc.32857

The tumor-stroma ratio (TSR) was evaluated as a promising parameter for breast cancer prognostication in clinically relevant subgroups of patients. The TSR was assessed on hematoxylin and eosin stained tissue slides of 1794 breast cancer patients fro... Read More about The prognostic value of the tumor–stroma ratio is most discriminative in patients with grade III or triple‐negative breast cancer.

Enhanced glutamine uptake influences composition of immune cell infiltrates in breast cancer (2019)
Journal Article
Ansari, R. E., Craze, M. L., Althobiti, M., Alfarsi, L., Ellis, I. O., Rakha, E. A., & Green, A. R. (2019). Enhanced glutamine uptake influences composition of immune cell infiltrates in breast cancer. British Journal of Cancer, 122(1), 94–101. https://doi.org/10.1038/s41416-019-0626-z

Background: Cancer cells must alter their metabolism to support proliferation. Immune evasion also plays a role in supporting tumour progression. This study aimed to find whether enhanced glutamine uptake in breast cancer (BC) can derive the existenc... Read More about Enhanced glutamine uptake influences composition of immune cell infiltrates in breast cancer.

Clinicopathological Characteristics of Basal-like Breast Cancer (BLBC): a Comparative Study between Egyptian and British Patients (2019)
Journal Article
Mohammed, R. A. A., El-Deek, H. E.-D. M., Aleskandarany, M. A., Green, A. R., Ellis, I. O., & Rakha, E. A. (2019). Clinicopathological Characteristics of Basal-like Breast Cancer (BLBC): a Comparative Study between Egyptian and British Patients. Egyptian Journal of Pathology, 16(1), 115-122. https://doi.org/10.4103/EGJP.EGJP_15_19

Background and aims: Clinicopathological features of Basal-like Breast Cancer (BLBC) in African American women have been extensively studied. Comparatively, less is known about these tumors in patients from countries in the North African region. The... Read More about Clinicopathological Characteristics of Basal-like Breast Cancer (BLBC): a Comparative Study between Egyptian and British Patients.

Dopamine and cAMP-regulated phosphoprotein 32 kDa (DARPP-32) and survival in breast cancer: a retrospective analysis of protein and mRNA expression (2019)
Journal Article
Kotecha, S., Lebot, M. N., Sukkarn, B., Ball, G., Moseley, P. M., Chan, S. Y., Green, A. R., Rakha, E., Ellis, I. O., Martin, S. G., & Storr, S. J. (2019). Dopamine and cAMP-regulated phosphoprotein 32 kDa (DARPP-32) and survival in breast cancer: a retrospective analysis of protein and mRNA expression. Scientific Reports, 9, 1-11. https://doi.org/10.1038/s41598-019-53529-z

Dopamine and cAMP regulated phosphoprotein 32 kDa (DARPP-32) also known as phosphoprotein phosphatase-1 regulatory subunit 1B and encoded by the PPP1R1B gene is an inhibitor of protein phosphatase-1 and protein kinase A. DARPP-32 is expressed in a wi... Read More about Dopamine and cAMP-regulated phosphoprotein 32 kDa (DARPP-32) and survival in breast cancer: a retrospective analysis of protein and mRNA expression.

Prognostic Significance of Nucleolar Assessment in Invasive Breast Cancer (2019)
Journal Article
Elsharawy, K. A., Toss, M. S., Raaft, S. R., Ball, G., Green, A. R., Aleskandarany, M. A., Dalton, L. W., & Rakha, E. A. (2020). Prognostic Significance of Nucleolar Assessment in Invasive Breast Cancer. Histopathology, 76(5), 671-684. https://doi.org/10.1111/his.14036

Aims: Nucleolar morphometric features have a potential role in the assessment of aggressiveness of many cancers. However, the role of nucleoli in invasive breast cancer (IBC) is still unclear. This study aimed to investigate the optimal scoring metho... Read More about Prognostic Significance of Nucleolar Assessment in Invasive Breast Cancer.

Clinicopathological significance of lipocalin 2 nuclear expression in invasive breast cancer (2019)
Journal Article
Kurozumi, S., Alsaeed, S., Orah, N., Miligy, I. M., Joseph, C., Aljohani, A., Toss, M. S., Fujii, T., Shirabe, K., Green, A. R., Aleskandarany, M. A., & Rakha, E. A. (2020). Clinicopathological significance of lipocalin 2 nuclear expression in invasive breast cancer. Breast Cancer Research and Treatment, 179, 557–564. https://doi.org/10.1007/s10549-019-05488-2

PURPOSE: The epithelial–mesenchymal transition (EMT) plays a key role in breast cancer progression and metastasis. Lipocalin 2 (LCN2) is involved in the regulation of EMT. The aim of this study was to investigate the clinicopathological significance... Read More about Clinicopathological significance of lipocalin 2 nuclear expression in invasive breast cancer.

Prognostic Significance of KN Motif and Ankyrin Repeat Domains 1 (KANK1) in Invasive Breast Cancer (2019)
Journal Article
Kariri, Y. A., Joseph, C., Kurozumi, S., Toss, M. S., Alsaleem, M., Raafat, S., Mongan, N. P., Aleskandarany, M. A., Green, A. R., & Rakha, E. A. (2020). Prognostic Significance of KN Motif and Ankyrin Repeat Domains 1 (KANK1) in Invasive Breast Cancer. Breast Cancer Research and Treatment, 179(2), 349–357. https://doi.org/10.1007/s10549-019-05466-8

Background: KN Motif and Ankyrin Repeat Domains 1 (KANK1) plays an important role in cytoskeleton maintenance and contributes to the regulation of cell proliferation, adhesion and apoptosis. KANK1 is involved in progression of a variety of solid tumo... Read More about Prognostic Significance of KN Motif and Ankyrin Repeat Domains 1 (KANK1) in Invasive Breast Cancer.

ATM Regulated PTEN Degradation Is XIAP E3 Ubiquitin Ligase Mediated in p85α Deficient Cancer Cells and Influence Platinum Sensitivity (2019)
Journal Article
Ali, R., Alabdullah, M., Miligy, I., Normatova, M., Babaei-Jadidi, R., S. Nateri, A., Rakha, E. A., & Madhusudan, S. (2019). ATM Regulated PTEN Degradation Is XIAP E3 Ubiquitin Ligase Mediated in p85α Deficient Cancer Cells and Influence Platinum Sensitivity. Cells, 8(10), Article 1271. https://doi.org/10.3390/cells8101271

Ataxia-telegiectasia mutated (ATM), phosphatase and tensin homolog (PTEN), and p85α are key tumour suppressors. Whether ATM regulates PTEN expression and influence platinum sensitivity is unknown. We generated ATM knockdowns (KD) and CRISPR knock out... Read More about ATM Regulated PTEN Degradation Is XIAP E3 Ubiquitin Ligase Mediated in p85α Deficient Cancer Cells and Influence Platinum Sensitivity.

The prognostic significance of wild type isocitrate dehydrogenase 2 (IDH2) in breast cancer (2019)
Journal Article
Aljohani, A. I., Toss, M. S., Kurozumi, S., Joseph, C., Aleskandarany, M. A., Miligy, I. M., Ansari, R. E., Mongan, N. P., Ellis, I. O., Green, A. R., & Rakha, E. (2020). The prognostic significance of wild type isocitrate dehydrogenase 2 (IDH2) in breast cancer. Breast Cancer Research and Treatment, 179(1), 79–90. https://doi.org/10.1007/s10549-019-05459-7

Background: Lymphovascular invasion (LVI) is a prerequisite step in breast cancer (BC) metastasis. We have previously identified wild type isocitrate dehydrogenase 2 (IDH2) as a key putative driver of LVI. Thus, we explored the prognostic significanc... Read More about The prognostic significance of wild type isocitrate dehydrogenase 2 (IDH2) in breast cancer.

The Role Of Glutaminase In Cancer (2019)
Journal Article
Masisi, B., El Ansari, R., Alfarsi, L., Rakha, E., Green, A., & Craze, M. (2020). The Role Of Glutaminase In Cancer. Histopathology, 76(4), 498-508. https://doi.org/10.1111/his.14014

Increased glutamine metabolism (glutaminolysis) is a hallmark of cancer and is recognised as a key metabolic change in cancer cells. As a heterogeneous disease with different morpholog- ical and molecular subtypes and response to therapy, breast canc... Read More about The Role Of Glutaminase In Cancer.

Retinoid X receptor gamma (RXRG) is an independent prognostic biomarker in ER-positive invasive breast cancer (2019)
Journal Article
Joseph, C., Al-Izzi, S., Alsaleem, M., Kurozumi, S., Toss, M., Arshad, M., Goh, F. Q., Alshankyty, I. M., Ali, S., Ellis, I. O., Mongan, N. P., Green, A. R., & Rakha, E. A. (2019). Retinoid X receptor gamma (RXRG) is an independent prognostic biomarker in ER-positive invasive breast cancer. British Journal of Cancer, 121(9), 776-785. https://doi.org/10.1038/s41416-019-0589-0

© 2019, The Author(s), under exclusive licence to Cancer Research UK. Background: Retinoid X Receptor Gamma (RXRG) is a member of the nuclear receptor superfamily and plays a role in tumour suppression. This study aims to explore the prognostic signi... Read More about Retinoid X receptor gamma (RXRG) is an independent prognostic biomarker in ER-positive invasive breast cancer.

The intra-tumoral stroma in patients with breast cancer increases with age (2019)
Journal Article
Vangangelt, K. M. H., Kramer, C. J. H., Bastiaannet, E., Putter, H., Cohen, D., van Pelt, G. W., Rakha, E. A., Green, A. R., Tollenaar, R. A. E. M., & Mesker, W. E. (2020). The intra-tumoral stroma in patients with breast cancer increases with age. Breast Cancer Research and Treatment, 179(1), 37–45. https://doi.org/10.1007/s10549-019-05422-6

Purpose
The tumor microenvironment in older patients is subject to changes. The tumor-stroma ratio (TSR) was evaluated in order to estimate the amount of intra-tumoral stroma and to evaluate the prognostic value of the TSR in older patients with br... Read More about The intra-tumoral stroma in patients with breast cancer increases with age.

CDC20 expression in oestrogen receptor positive breast cancer predicts poor prognosis and lack of response to endocrine therapy (2019)
Journal Article
Alfarsi, L., Ansari, R. E., Craze, M. L., Toss, M. S., Masisi, B., Ellis, I. O., Rakha, E. A., & Green, A. R. (2019). CDC20 expression in oestrogen receptor positive breast cancer predicts poor prognosis and lack of response to endocrine therapy. Breast Cancer Research and Treatment, 178(3), 535-544. https://doi.org/10.1007/s10549-019-05420-8

Purpose
Endocrine therapy is the standard treatment for oestrogen receptor positive (ER+) breast cancer. Despite its efficacy, around half of patients will develop resistance to this treatment and eventually relapse. Identification of effective and... Read More about CDC20 expression in oestrogen receptor positive breast cancer predicts poor prognosis and lack of response to endocrine therapy.

Prognostic significance of cathepsin V (CTSV/CTSL2) in breast ductal carcinoma in situ (2019)
Journal Article
Toss, M. S., Miligy, I. M., Gorringe, K. L., Mittal, K., Green, A. R., Aneja, R., Ellis, I. O., & Rakha, E. A. (2020). Prognostic significance of cathepsin V (CTSV/CTSL2) in breast ductal carcinoma in situ. Journal of Clinical Pathology, 73(2), 76-82. https://doi.org/10.1136/jclinpath-2019-205939

Aims: Cathepsin V (CTSV/CTSL2) is a lysosomal cystine proteinase and plays a role in extracellular matrix degradation. It is associated with poor prognosis in invasive breast cancer (IBC), but its role in breast ductal carcinoma in situ (DCIS) remain... Read More about Prognostic significance of cathepsin V (CTSV/CTSL2) in breast ductal carcinoma in situ.

Machine learning-based prediction of breast cancer growth rate in-vivo (2019)
Journal Article
Bhattarai, S., Klimov, S., Aleskandarany, M. A., Burrell, H., Wormall, A., Green, A. R., Rida, P., Ellis, I. O., Osan, R. M., Rakha, E. A., & Aneja, R. (2019). Machine learning-based prediction of breast cancer growth rate in-vivo. British Journal of Cancer, 121, 497–504. https://doi.org/10.1038/s41416-019-0539-x

Background
Determining the rate of breast cancer (BC) growth in vivo, which can predict prognosis, has remained elusive despite its relevance for treatment, screening recommendations and medicolegal practice. We developed a model that predicts the r... Read More about Machine learning-based prediction of breast cancer growth rate in-vivo.

Whole‐exome sequencing and RNA sequencing analyses of acinic cell carcinomas of the breast (2019)
Journal Article
Beca, F., Lee, S. S., Pareja, F., da Cruz Paula, A., Selenica, P., Ferrando, L., Gularte‐Merida, R., Wen, H. Y., Zhang, H., Guerini‐Rocco, E., Rakha, E. A., Weigelt, B., & Reis‐Filho, J. S. (2019). Whole‐exome sequencing and RNA sequencing analyses of acinic cell carcinomas of the breast. Histopathology, 75(6), 931-937. https://doi.org/10.1111/his.13962

Aims
Acinic cell carcinoma of the breast (ACC) is a rare histologic form of triple‐negative breast cancer (TNBC). Despite its unique histology, targeted sequencing analysis has failed to identify recurrent genetic alterations other than those found... Read More about Whole‐exome sequencing and RNA sequencing analyses of acinic cell carcinomas of the breast.

A whole slide image-based machine learning approach to predict ductal carcinoma in situ (DCIS) recurrence risk (2019)
Journal Article
Klimov, S., Miligy, I. M., Gertych, A., Jiang, Y., Toss, M. S., Rida, P., Ellis, I. O., Green, A., Krishnamurti, U., Rakha, E. A., & Aneja, R. (2019). A whole slide image-based machine learning approach to predict ductal carcinoma in situ (DCIS) recurrence risk. Breast Cancer Research, 21(1), Article 83. https://doi.org/10.1186/s13058-019-1165-5

© 2019 The Author(s). Background: Breast ductal carcinoma in situ (DCIS) represent approximately 20% of screen-detected breast cancers. The overall risk for DCIS patients treated with breast-conserving surgery stems almost exclusively from local recu... Read More about A whole slide image-based machine learning approach to predict ductal carcinoma in situ (DCIS) recurrence risk.